Thank you for visiting
TREXIMET.com

You are about to leave the TREXIMET® (sumatriptan/naproxen sodium) website and enter a website operated by an independent third party. The links to the third-party websites contained in TREXIMET.com are provided for your convenience. Currax Pharmaceuticals LLC does not control the opinions or claims contained in any third-party website linked to TREXIMET.com. The policies and practices of third-party websites may differ from ours.

Would you like to leave TREXIMET.com?

Treximet (sumatriptan/naproxen sodium) | Rapid, sustained relief

You can get TREXIMET® for $25*

Click here to get your savings card

*Some restrictions apply.

 

There is only one brand-name TREXIMET®

FOR PATIENTS: 3 TIPS TO GET BRAND-NAME TREXIMET

  • At your doctor’s office: Ask your doctor to prescribe brand-name TREXIMET® and to indicate "DAW" (Dispense As Written)—or the language used in your state—on all of your TREXIMET® prescriptions.
  • At your pharmacy's drop-off: Tell the pharmacist that you want brand-name TREXIMET®—and be sure to use the TREXIMET® Savings Card if eligible.
  • At your pharmacy's pick-up: Check your pills to be sure they're brand-name TREXIMET®—not the generic—and also check that you've saved on your prescription if eligible.

Make TREXIMET® Your
First Choice
to treat acute MIGRAINE

TREXIMET® is the only fixed-dose sumatriptan/naproxen combination designed to address distinct aspects of acute migraine.1,2

Only brand-name TREXIMET® is formulated with Rapid-release RT Technology, not available in generic sumatriptan tablets, which ensures rapid medication dispersion.3

TREXIMET is a registered trademark of Currax Pharmaceuticals LLC. All other trademarks are property of their respective owners.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions].
  • TREXIMET® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications, Warnings and Precautions].

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions].

INDICATION

TREXIMET® (sumatriptan and naproxen sodium) is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal anti-inflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.

LIMITATIONS OF USE

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were:

DRUG INTERACTIONS

You are encouraged to report negative side effects of taking TREXIMET® to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

To report adverse events, a product complaint, or for additional information about TREXIMET®, call Currax Pharmaceuticals LLC at 1-800-793-2145.

Please see Full Prescribing Information, including Boxed WARNINGS, before prescribing TREXIMET®.

References: 1. TREXIMET® Prescribing Information. Morristown, NJ: Currax Pharmaceuticals LLC. July 2019. 2. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443-1454. 3. Data on file, Currax Pharmaceuticals LLC.

This web site is intended only for residents of the United States.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions].
  • TREXIMET® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications, Warnings and Precautions].

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions].

INDICATION

TREXIMET® (sumatriptan and naproxen sodium) is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal anti-inflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.

LIMITATIONS OF USE

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were:

DRUG INTERACTIONS

You are encouraged to report negative side effects of taking TREXIMET® to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

To report adverse events, a product complaint, or for additional information about TREXIMET®, call Currax Pharmaceuticals LLC at 1-800-793-2145.

Please see Full Prescribing Information, including Boxed WARNINGS, before prescribing TREXIMET®.

References: 1. TREXIMET® Prescribing Information. Morristown, NJ: Currax Pharmaceuticals LLC. July 2019. 2. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443-1454. 3. Data on file, Currax Pharmaceuticals LLC.

This web site is intended only for residents of the United States.

Back to Top